Exploring Biliary Tract Cancer: Top Takeaways From ASCO GI 2025 - Episode 11

Clinical Insights: Incorporating Zanidatamab and Other HER2-Targeted Agents Into the Real-World Practice in Advanced BTC

March 26, 2025

Shubham Pant, MD, Haley Ellis, MD , Amit Mahipal, MD, Darshil Shah, MD, MPH

Panelists discuss how treatment selection among HER2-targeted agents for biliary tract cancer (BTC) depends on multiple factors including patient characteristics and prior therapies, while also considering the role of traditional chemotherapy regimens such as FOLFOX in specific clinical scenarios.

Video Player is loading.

Current Time 0:00

Duration 0:00

Loaded: 0%

Stream Type LIVE

Remaining Time 0:00

EP. 1: Guiding Patients Through Advanced BTC Prognosis and Expectations

EP. 2: The Importance of Early Biomarker Testing in Managing Advanced BTC

EP. 3: Biomarker Testing in BTC: Approaches and Practices Across Academic and Community Clinicians

EP. 4: Expert Insights: Challenges With ctDNA Testing in BTC

EP. 5: Landmark Trials in First-Line Treatment Landscape for Advanced BTC: Expert Insights from TOPAZ-1 and KEYNOTE-966 Trials

EP. 6: Applying Data to Clinical Practice: Immunotherapy in the First-Line Treatment Setting in Advanced BTC

EP. 7: Understanding HER2 Testing in BTC: Detection and Clinical Approaches

EP. 8: Expert Perspectives From DESTINY-PanTumor 02 and Real-World Experience with Trastuzumab Deruxtecan in HER2-Positive BTC

EP. 9: New Approvals in HER2-Positive BTC: Zanidatamab - Key Findings from HERIZON-BTC-01 Study

EP. 10: Expert Perspectives in HER2-Positive BTC: Trastuzumab With Pertuzumab or Tucatinib From MyPathway and SGNTUC-019 Trials

Now Viewing

EP. 11: Clinical Insights: Incorporating Zanidatamab and Other HER2-Targeted Agents Into the Real-World Practice in Advanced BTC

EP. 12: Future Perspectives and Unmet Needs in HER2-Positive Advanced BTC Treatment

EP. 13: Key Takeaways From ASCO GI 2025: Exciting Updates on BTC

Video content above is prompted by the following:

What is your general treatment approach when deciding among the available HER2-targeted agents? For those with HER2-positive tumors, are there situations in which you may still proceed with a 5-FU–containing regimen such as FOLFOX?
Please comment on any differences and/or similarities in practice regarding HER2-directed therapy selection. Please describe any specific patient and/or disease factors considerations in your treatment approach.